ArticleJournal of the Endocrine Society2019
Immune Checkpoint Blockade Anti-PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome.
Article in Journal of the Endocrine Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Anticancer Drugs-Related Hypogonadism in Male Patients with Advanced Cancers on Active Treatment: A Systematic Review.The oncologist · 2024Pooled it
- Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline.European journal of endocrinology · 2022Guideline
- Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review.Cancer immunology, immunotherapy : CII · 2021Pooled it
- Case Report: Successful rechallenge of cadonilimab-induced cystitis, adrenal insufficiency, and diabetic ketoacidosis in a patient with metastatic gastric-type endocervical adenocarcinoma.Frontiers in oncology · 2026Article
- Beyond Tumor Immunity: The Disruption of Endocrine and Infectious Homeostasis by Immune Checkpoint Inhibitors.International journal of molecular sciences · 2025Review
- Concomitant Immune Checkpoint Inhibitors Induced Central and Primary Adrenal Insufficiency: A Diagnostic Challenge.JCEM case reports · 2025Article
- Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors.Nature reviews. Endocrinology · 2025Review
- Challenges and pitfalls in the management of endocrine toxicities from immune checkpoint inhibitors: a case presentation of synchronous thyrotoxicosis and primary adrenal insufficiency in a melanoma patient.Hormones (Athens, Greece) · 2024Article
- A Case in Which HLA-DR4 is Involved in the Development of Complex Immune-Related Endocrinological Adverse Events following Combination Therapy with Nivolumab and Ipilimumab.Case reports in endocrinology · 2024Article
- Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Review
- Autoantibodies involved in primary and secondary adrenal insufficiency following treatment with immune checkpoint inhibitors.Immuno-oncology technology · 2023Review
- Endocrine side effects of immune checkpoint inhibitors.Frontiers in endocrinology · 2023Review
- Beyond Cancer: Regulation and Function of PD-L1 in Health and Immune-Related Diseases.International journal of molecular sciences · 2022Review
- Atezolizumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis and Takotsubo cardiomyopathy.BMJ case reports · 2022Article
- Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-induced Endocrinopathy: A Prospective Study.The Journal of clinical endocrinology and metabolism · 2022Article
- Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients.BMC endocrine disorders · 2022Article
- Polyendocrine Autoimmunity and Diabetic Ketoacidosis Following Anti-PD-1 and Interferon α.Pediatrics · 2022Article
- Autoimmune Polyendocrinopathy Induced by an Antibody (KN046) That Simultaneously Inhibits PD-L1 and CTLA-4: A Case Report and Literature Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- Thyroid-related adverse events induced by immune checkpoint inhibitors.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextThe programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) pathway is a key regulator in T-cell activation and tolerance, limiting effector T-cell function in peripheral tissues. Atezolizumab, an anti-PD-L1 monoclonal antibody, is approved for treatment of some types of advanced cancer. Its main treatment-related adverse events are immune related, such as thyroid dysfunction and hypophysitis. Autoimmune endocrinopathy can occur as isolated manifestations; only a few cases of autoimmune polyendocrine syndromes have been reported thus far. CASE: We report a case of polyendocrine syndrome type 2, characterized by Addison disease (AD), type 1 diabetes mellitus (T1DM), accompanied by hypophysitis, in a patient treated with atezolizumab. Testing was positive for 21-hydroxylase and pituitary antibodies and negative for islet cells antibodies. HLA typing revealed DRB1*04 and DQB1*03 haplotypes, which are associated with increased susceptibility to T1DM and AD.
conclusionThe type and severity of immune-related adverse events in polyendocrine syndrome type 2 are different and depend on the monoclonal antibody used. Although the numerous molecular mechanisms inducing autoimmune endocrine diseases are still unclear, a link exists between HLA haplotypes, gene variants involved in immune checkpoint molecule expression, and increased susceptibility to autoimmune endocrinopathies. Additional studies are needed to identify susceptible patients and adapt therapy to each patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.